Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Susan Calcaterra to Opioid-Related Disorders

This is a "connection" page, showing publications Susan Calcaterra has written about Opioid-Related Disorders.

 
Connection Strength
  
 
 
8.824
  
  1. Calcaterra SL, Weimer MB, Grimm E, Scherbak Y, Abdel Galil R, Berger O, Bowman LA, Nesbit SA, Barany A, Buresh ME. Leveraging the 72-Hour Rule Change to Support Transition From Hospital to Opioid Treatment Program. JAMA Netw Open. 2025 11 03; 8(11):e2544996.
    View in: PubMed
    Score: 0.511
  2. Calcaterra SL, Lockhart S, Natvig C, Mikulich-Gilbertson SK. Measuring the Impact of a Multi-Site In-Hospital Intervention for Opioid Use Disorder Treatment Provision: A Survey of Hospital-Based Clinicians. J Gen Intern Med. 2026 03; 41(4):1048-1057.
    View in: PubMed
    Score: 0.505
  3. Sandhu S, Calcaterra SL. How Do I Manage Acute Pain for Patients Prescribed Buprenorphine for Opioid Use Disorder? NEJM Evid. 2024 May; 3(5):EVIDccon2300275.
    View in: PubMed
    Score: 0.460
  4. Calcaterra SL, Dafoe A, Tietbohl C, Thurman L, Bredenberg E. Unintended consequences of methadone regulation for opioid use disorder treatment among hospitalized patients. J Hosp Med. 2024 06; 19(6):460-467.
    View in: PubMed
    Score: 0.457
  5. Calcaterra SL, Saunders S, Grimm E, Maki-Gianani E, Keniston A, Wold A, Bonaguidi A. In-Hospital Methadone Enrollment: a Novel Program to Facilitate Linkage from the Hospital to the Opioid Treatment Program for Vulnerable Patients with Opioid Use Disorder. J Gen Intern Med. 2024 02; 39(3):385-392.
    View in: PubMed
    Score: 0.441
  6. Calcaterra SL, Lockhart S, Natvig C, Mikulich S. Barriers to initiate buprenorphine and methadone for opioid use disorder treatment with postdischarge treatment linkage. J Hosp Med. 2023 10; 18(10):896-907.
    View in: PubMed
    Score: 0.439
  7. Martin M, Englander H, Calcaterra SL. Things We Do for No Reason?: Avoiding methadone for opioid withdrawal. J Hosp Med. 2023 11; 18(11):1034-1037.
    View in: PubMed
    Score: 0.432
  8. Calcaterra SL, Martin M, Englander H. Identifying Barriers to OUD Treatment Linkage From the Emergency Department to the Community. JAMA Netw Open. 2023 05 01; 6(5):e2312683.
    View in: PubMed
    Score: 0.430
  9. Calcaterra SL, Buresh M, Weimer MB. Better care at the bedside for hospitalized patients with opioid use disorder. J Hosp Med. 2023 12; 18(12):1134-1138.
    View in: PubMed
    Score: 0.428
  10. Calcaterra SL, Grimm E, Keniston A. External validation of a model to predict future chronic opioid use among hospitalized patients. J Hosp Med. 2023 02; 18(2):154-162.
    View in: PubMed
    Score: 0.419
  11. Calcaterra SL, Martin M, Bottner R, Englander H, Weinstein Z, Weimer MB, Lambert E, Herzig SJ. Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine. J Hosp Med. 2022 09; 17(9):744-756.
    View in: PubMed
    Score: 0.408
  12. Calcaterra SL, Bottner R, Martin M, Englander H, Weinstein ZM, Weimer MB, Lambert E, Ronan MV, Huerta S, Zaman T, Ullal M, Peterkin AF, Torres-Lockhart K, Buresh M, O'Brien MT, Snyder H, Herzig SJ. Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines. J Hosp Med. 2022 09; 17(9):679-692.
    View in: PubMed
    Score: 0.408
  13. Calcaterra SL, Lockhart S, Callister C, Hoover K, Binswanger IA. Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers. J Gen Intern Med. 2022 08; 37(11):2786-2794.
    View in: PubMed
    Score: 0.392
  14. Callister C, Lockhart S, Holtrop JS, Hoover K, Calcaterra SL. Experiences with an addiction consultation service on care provided to hospitalized patients with opioid use disorder: a qualitative study of hospitalists, nurses, pharmacists, and social workers. Subst Abus. 2022; 43(1):615-622.
    View in: PubMed
    Score: 0.386
  15. Calcaterra SL, Binswanger IA, Edelman EJ, McNair BK, Wakeman SE, O'Connor PG. The impact of access to addiction specialist on attitudes, beliefs and hospital-based opioid use disorder related care: A survey of hospitalist physicians. Subst Abus. 2022; 43(1):143-151.
    View in: PubMed
    Score: 0.348
  16. Calcaterra SL, Klie KA. Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis. Obstet Gynecol. 2020 04; 135(4):975.
    View in: PubMed
    Score: 0.347
  17. Terasaki D, Smith C, Calcaterra SL. Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol. Pharmacotherapy. 2019 10; 39(10):1023-1029.
    View in: PubMed
    Score: 0.332
  18. Calcaterra SL, Bach P, Chadi A, Chadi N, Kimmel SD, Morford KL, Roy P, Samet JH. Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction. J Gen Intern Med. 2019 06; 34(6):1039-1042.
    View in: PubMed
    Score: 0.321
  19. Calcaterra SL, Scarbro S, Hull ML, Forber AD, Binswanger IA, Colborn KL. Prediction of Future Chronic Opioid Use Among Hospitalized Patients. J Gen Intern Med. 2018 06; 33(6):898-905.
    View in: PubMed
    Score: 0.299
  20. Calcaterra SL, Yamashita TE, Min SJ, Keniston A, Frank JW, Binswanger IA. Opioid Prescribing at Hospital Discharge Contributes to Chronic Opioid Use. J Gen Intern Med. 2016 May; 31(5):478-85.
    View in: PubMed
    Score: 0.265
  21. Calcaterra S, Glanz J, Binswanger IA. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999-2009. Drug Alcohol Depend. 2013 Aug 01; 131(3):263-70.
    View in: PubMed
    Score: 0.210
  22. Scherbak Y, Wehrer M, Jacknin G, Nelson A, Calcaterra S. Bridging the Gap: Empowering Pharmacists in Inpatient Injectable Naltrexone and Hospital-Dispensed Methadone Process Development. J Am Coll Clin Pharm. 2026 Mar; 9(3):e70186.
    View in: PubMed
    Score: 0.131
  23. Callister C, Porter S, Vatterott P, Keniston A, McBeth L, Mann S, Calcaterra SL, Limes J. The Impact of Completing X-Waiver Training and Clinical Addiction Exposure on Internal Medicine Residents Treating Patients With Opioid Use Disorder. Subst Use Addctn J. 2024 07; 45(3):356-366.
    View in: PubMed
    Score: 0.113
  24. Terasaki D, Kulick B, Calcaterra S, Ray L. Phenobarbital for alcohol withdrawal in the context of the opioid epidemic: a neglected caveat. Addiction. 2023 07; 118(7):1198-1200.
    View in: PubMed
    Score: 0.107
  25. Ritvo AD, Calcaterra SL, Ritvo JI. Using Extended Release Buprenorphine Injection to Discontinue Sublingual Buprenorphine: A Case Series. J Addict Med. 2021 May-Jun 01; 15(3):252-254.
    View in: PubMed
    Score: 0.094
  26. Herzig SJ, Mosher HJ, Calcaterra SL, Nuckols TK. Reply to "In Reference to 'Improving the Safety of Opioid Use for Acute Noncancer Pain in Hospitalized Adults: A Consensus Statement from the Society of Hospital Medicine'". J Hosp Med. 2018 09; 13(10):728.
    View in: PubMed
    Score: 0.078
  27. Frank JW, Levy C, Calcaterra SL, Hoppe JA, Binswanger IA. Naloxone Administration in US Emergency Departments, 2000-2011. J Med Toxicol. 2016 06; 12(2):148-56.
    View in: PubMed
    Score: 0.067
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)